PF-07104091

• CAT Number: I034511
• CAS Number: 2460249-19-6
• Molecular Formula: C19H28N6O4
• Molecular Weight: 404.47
• Purity: 98%
• Synonyms: PF-07104091; PF 07104091; PF07104091; PF-7104091; PF 7104091; PF7104091
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Store at -20°C
• IUPAC Name: (1R,3S)-3-(3-(3-(methoxymethyl)-1-methyl-1H-pyrazole-5-carboxamido)-1H-pyrazol-5-yl)cyclopentyl isopropylcarbamate
• InChI: InChI=1S/C19H28N6O4/c1-11(2)20-19(27)29-14-6-5-12(7-14)15-9-17(23-22-15)21-18(26)16-8-13(10-28-4)24-25(16)3/h8-9,11-12,14H,5-7,10H2,1-4H3,(H,20,27)(H2,21,22,23,26)/t12-,14+/m0/s1
• InChIKey: MTNBRBDFNSGQKB-GXTWGEPZSA-N
• SMILES: O=C(C1=CC(COC)=NN1C)NC2=NNC([C@](CC3)([H])C[C@@H]3OC(NC(C)C)=O)=C2

PF-07104091（Cat No.:I034511）, is an orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2) with potential antineoplastic activity. It selectively targets and inhibits CDK2, leading to cell cycle arrest, apoptosis induction, and inhibition of tumor cell proliferation. CDK2 is a serine/threonine kinase that regulates cell cycle progression and is often overexpressed in cancer cells. CDK2 complexes with cyclin E and cyclin A, play vital roles in the G1-S and S phase transitions, as well as DNA synthesis and G2-M phase transition, respectively. PF-07104091 shows promise as a therapeutic agent against cancer.